Tessara Therapeutics Pty Ltd

Tessara Therapeutics is a Melbourne-based biotechnology company transforming drug discovery through its proprietary RealBrain® platform. Tessara has pioneered the first scalable, reproducible 3D human brain micro-tissue models that accurately replicate neural physiology of healthy and diseased neural tissues. Unlike traditional 2D cell cultures, or current 3D models such as spheroids and organoids, RealBrain mimics the architecture and function of the human brain while enabling cost-effective and high-throughput screening. Tessara’s models include ArtiBrain™ (healthy brain) and ADBrain™ (sporadic Alzheimer’s disease, representing ~98% of all AD cases), both built from stem cell-derived neural precursors encapsulated in a chemically defined hydrogel that drives in vitro neurodevelopment.

What sets Tessara apart is its ability to deliver predictive and reproducible models compatible with advanced analytical tools, from genomics to high-content imaging. These models not only support the industry-wide shift toward human-relevant, non-animal research but also accelerate discovery timelines and increases the chances of successful clinical trials.

Tessara operates a hybrid business model: revenue is generated through direct sales of human brain micro-tissues to neuroscience innovators and service providers, custom co-development partnerships, and data-driven screening services for biopharma companies. This flexible, scalable approach positions Tessara as a critical enabler in the preclinical neuroscience and neurodegeneration drug discovery ecosystem.